This means that the adrenergic stress inside the tumor microenvironment can negatively impact the metabolic profile of CAR-T cells, and that any intervention for blocking β2-AR in T lymphocytes might be a potential strategy to boost the efficacy of CAR-T cell therapy. This evidence concerns the gene ADRB2 and neoplasm.